ResMed (RMD) to Release Quarterly Earnings on Thursday

ResMed (NYSE:RMD) is scheduled to issue its quarterly earnings data after the market closes on Thursday, October 24th. Analysts expect the company to announce earnings of $2.03 per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.05. ResMed had a return on equity of 25.00% and a net margin of 21.79%. The firm had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.22 billion. During the same period last year, the business posted $1.60 earnings per share. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. On average, analysts expect ResMed to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

ResMed Trading Up 0.0 %

Shares of NYSE:RMD opened at $240.05 on Tuesday. ResMed has a 52-week low of $132.24 and a 52-week high of $255.18. The stock has a market cap of $35.27 billion, a price-to-earnings ratio of 36.87, a PEG ratio of 2.17 and a beta of 0.69. The company has a quick ratio of 1.69, a current ratio of 2.59 and a debt-to-equity ratio of 0.14. The business has a 50-day moving average price of $239.29 and a 200-day moving average price of $216.70.

ResMed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 19th. Stockholders of record on Thursday, August 15th were paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 0.88%. This is a boost from ResMed’s previous quarterly dividend of $0.48. The ex-dividend date was Thursday, August 15th. ResMed’s dividend payout ratio (DPR) is presently 32.57%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on RMD shares. Baird R W upgraded ResMed to a “strong-buy” rating in a research note on Tuesday, September 24th. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research note on Tuesday, October 1st. Bank of America lifted their price target on ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a research report on Thursday, September 26th. Royal Bank of Canada lifted their price target on ResMed from $206.00 to $224.00 and gave the company a “sector perform” rating in a research report on Tuesday, October 1st. Finally, StockNews.com upgraded ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $218.18.

Insider Activity

In other news, insider Justin Leong sold 48,000 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $217.07, for a total value of $10,419,360.00. Following the completion of the sale, the insider now directly owns 18,741 shares in the company, valued at $4,068,108.87. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Justin Leong sold 48,000 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $217.07, for a total value of $10,419,360.00. Following the completion of the sale, the insider now directly owns 18,741 shares in the company, valued at $4,068,108.87. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kaushik Ghoshal sold 4,260 shares of the business’s stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $238.48, for a total value of $1,015,924.80. Following the completion of the sale, the insider now owns 21,788 shares of the company’s stock, valued at $5,196,002.24. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 123,874 shares of company stock worth $28,151,142 over the last three months. 1.21% of the stock is currently owned by corporate insiders.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.